

ARES ALLERGY HOLDINGS PLC



COMBINATION OF STALLERGENES AND GREER LABORATORIES:

END OF THE LIQUIDITY CONTRACT FOR STALLERGENES SHARES

**IMPLEMENTATION OF A LIQUIDITY CONTRACT FOR ARES ALLERGY SHARES
AS OF THE ADMISSION TO TRADING OF ARES ALLERGY SHARES**

London (United Kingdom), 31 August 2015 – STALLERGENES announces that the liquidity contract it has in place with Oddo Corporate Finance relating to STALLERGENES shares will terminate August 31, 2015.

Ares Allergy Holdings PLC (“Ares Allergy”) will enter into a liquidity contract to take effect upon admission to trading of the Ares Allergy shares on the Euronext Paris regulated market, i.e., based on the indicative timetable, on 8 September 2015.

Ares Allergy will entrust Oddo Corporate Finance with the implementation of the liquidity contract for the Ares Allergy shares in compliance with the AMAFI's Ethics Charter approved by the Autorité des Marchés Financiers on 21 March 2011. It is anticipated that a sum of €2 million will be allocated to the liquidity account for implementation of this contract.

ABOUT ARES ALLERGY HOLDINGS PLC

Headquartered in London (UK), Ares Allergy is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and provision of allergy immunotherapy products and services. Ares Allergy is the parent company of Greer Laboratories, Inc. (whose registered office is in the U.S.) and will become the parent company of Stallergenes SA (whose registered office is in France and which is listed on Euronext Paris) upon completion of the merger of Stallergenes SA with and into Ares Allergy.

Contacts:

UK: Robin Wrench, Brunswick Group

Email: waypoint@brunswickgroup.com

Tel. +44 (0)20 7404 5959

Forward-looking statements related to Ares Allergy Holdings Plc

This press release may contain forward-looking statements concerning the proposed combination and the benefits expected. Such statements are based upon the current beliefs and expectations of Ares Allergy Holdings Plc's management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. Ares Allergy Holdings Plc disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Restrictions:

This document cannot be released directly or indirectly in South Africa, Australia, Canada, Japan, New Zealand or the United States of America. The information contained in this document does not constitute an offer to sell or the solicitation of an offer to buy or sell shares or other financial instruments in Ares Allergy Holdings Plc or Stallergenes SA in any jurisdiction, in particular in any jurisdiction in which such an offer, solicitation, purchase or sale would be illegal prior to the registration, exemption from registration or other qualification under the terms of legislation on financial instruments in such a jurisdiction. Persons in possession of this document are required to inform themselves about and comply with these restrictions. Neither Stallergenes SA, nor Ares Allergy Holdings Plc or any other party to this transaction mentioned in this document accepts any liability in respect of persons who have obtained this document in violation of these restrictions. Shares in Ares Allergy Holdings have not been and will not be registered under the US Securities Act of 1933 or under any other legislation of any jurisdiction in the United States of America.